These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 26743031)

  • 21. Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway.
    Feng J; Yan PF; Zhao HY; Zhang FC; Zhao WH; Feng M
    Biomed Res Int; 2016; 2016():1450843. PubMed ID: 28097126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploiting tumor vulnerabilities: NAD(+)-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies.
    Cea M; Soncini D; Gobbi M; Lemoli RM; Cagnetta A
    Expert Rev Anticancer Ther; 2016 Sep; 16(9):897-8. PubMed ID: 27433930
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA approves IDH1 and IDH2 inhibitor for brain cancer.
    Mullard A
    Nat Rev Drug Discov; 2024 Oct; 23(10):731. PubMed ID: 39152244
    [No Abstract]   [Full Text] [Related]  

  • 24. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
    Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
    Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells.
    Gehrke I; Bouchard ED; Beiggi S; Poeppl AG; Johnston JB; Gibson SB; Banerji V
    Clin Cancer Res; 2014 Sep; 20(18):4861-72. PubMed ID: 25172933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
    Zabka TS; Singh J; Dhawan P; Liederer BM; Oeh J; Kauss MA; Xiao Y; Zak M; Lin T; McCray B; La N; Nguyen T; Beyer J; Farman C; Uppal H; Dragovich PS; O'Brien T; Sampath D; Misner DL
    Toxicol Sci; 2015 Mar; 144(1):163-72. PubMed ID: 25505128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.
    Barraud M; Garnier J; Loncle C; Gayet O; Lequeue C; Vasseur S; Bian B; Duconseil P; Gilabert M; Bigonnet M; Maignan A; Moutardier V; Garcia S; Turrini O; Delpero JR; Giovannini M; Grandval P; Gasmi M; Ouaissi M; Secq V; Poizat F; Guibert N; Iovanna J; Dusetti N
    Oncotarget; 2016 Aug; 7(33):53783-53796. PubMed ID: 27462772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
    Zheng X; Bair KW; Bauer P; Baumeister T; Bowman KK; Buckmelter AJ; Caligiuri M; Clodfelter KH; Feng Y; Han B; Ho YC; Kley N; Li H; Liang X; Liederer BM; Lin J; Ly J; O'Brien T; Oeh J; Oh A; Reynolds DJ; Sampath D; Sharma G; Skelton N; Smith CC; Tremayne J; Wang L; Wang W; Wang Z; Wu H; Wu J; Xiao Y; Yang G; Yuen PW; Zak M; Dragovich PS
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5488-97. PubMed ID: 24021463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Nampt inhibitor FK866 mimics vitamin B3 deficiency by causing senescence of human fibroblastic Hs68 cells via attenuation of NAD(+)-SIRT1 signaling.
    Song TY; Yeh SL; Hu ML; Chen MY; Yang NC
    Biogerontology; 2015 Dec; 16(6):789-800. PubMed ID: 26330291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry.
    Colombano G; Travelli C; Galli U; Caldarelli A; Chini MG; Canonico PL; Sorba G; Bifulco G; Tron GC; Genazzani AA
    J Med Chem; 2010 Jan; 53(2):616-23. PubMed ID: 19961183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines.
    Misner DL; Kauss MA; Singh J; Uppal H; Bruening-Wright A; Liederer BM; Lin T; McCray B; La N; Nguyen T; Sampath D; Dragovich PS; O'Brien T; Zabka TS
    Cardiovasc Toxicol; 2017 Jul; 17(3):307-318. PubMed ID: 27783203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reader Response: Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wild-Type Glioblastoma in Adults: An Observational Study.
    Mazzucchi E; Pauletto G; Sabatino G; Ius T
    Neurology; 2022 Jul; 99(2):84-85. PubMed ID: 35817574
    [No Abstract]   [Full Text] [Related]  

  • 33. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.
    Tateishi K; Iafrate AJ; Ho Q; Curry WT; Batchelor TT; Flaherty KT; Onozato ML; Lelic N; Sundaram S; Cahill DP; Chi AS; Wakimoto H
    Clin Cancer Res; 2016 Sep; 22(17):4452-65. PubMed ID: 27076630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Author Response: Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wild-Type Glioblastoma in Adults: An Observational Study.
    Pallud J; Huberfeld G
    Neurology; 2022 Jul; 99(2):85. PubMed ID: 35817573
    [No Abstract]   [Full Text] [Related]  

  • 35. Reader Response: Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wild-Type Glioblastoma in Adults: An Observational Study.
    Mazzucchi E; Pauletto G; Sabatino G; Ius T
    Neurology; 2022 Jun; 98(23):992-993. PubMed ID: 35667845
    [No Abstract]   [Full Text] [Related]  

  • 36. Author Response: Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wild-Type Glioblastoma in Adults: An Observational Study.
    Pallud J; Huberfeld G
    Neurology; 2022 Jun; 98(23):993. PubMed ID: 35667844
    [No Abstract]   [Full Text] [Related]  

  • 37. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
    Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
    Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
    Sociali G; Raffaghello L; Magnone M; Zamporlini F; Emionite L; Sturla L; Bianchi G; Vigliarolo T; Nahimana A; Nencioni A; Raffaelli N; Bruzzone S
    Oncotarget; 2016 Jan; 7(3):2968-84. PubMed ID: 26658104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NAMPT inhibitor and metabolite protect mouse brain from cryoinjury through distinct mechanisms.
    Zhang XQ; Lu JT; Jiang WX; Lu YB; Wu M; Wei EQ; Zhang WP; Tang C
    Neuroscience; 2015 Apr; 291():230-40. PubMed ID: 25684751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia.
    Somers K; Evans K; Cheung L; Karsa M; Pritchard T; Kosciolek A; Bongers A; El-Ayoubi A; Forgham H; Middlemiss S; Mayoh C; Jones L; Gupta M; Kees UR; Chernova O; Korotchkina L; Gudkov AV; Erickson SW; Teicher B; Smith MA; Norris MD; Haber M; Lock RB; Henderson MJ
    Leukemia; 2020 Jun; 34(6):1524-1539. PubMed ID: 31848452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.